Drug evaluation: Tagatose in the treatment of type 2 diabetes and obesity

by M C Moore
Current Opinion in Investigational Drugs ()


Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed. © The Thomson Corporation.

Cite this document (BETA)

Readership Statistics

2 Readers on Mendeley
by Discipline
by Academic Status
50% Ph.D. Student
50% Student (Master)
by Country
50% Brazil

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in